Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Arthritis Health Center

Font Size

FDA OKs New Gout Drug Uloric

Uloric is First New Gout Drug in More Than 40 Years
WebMD Health News
Reviewed by Louise Chang, MD

Feb. 16, 2009 -- The FDA has approved Uloric, the first new gout drug in more than 40 years, according to Uloric's maker, Takeda Pharmaceuticals.

Uloric, taken once daily by mouth, is approved for the chronic management of hyperuricemia (elevated levels of uric acid) in gout patients.

Uloric works by blocking an enzyme called xanthine oxidase, which helps prevent uric acid production, lowering elevated uric acid levels, according to Takeda.

In 2005, the FDA refused to approve Uloric because there were slightly more deaths and heart problems in patients taking the drug than in patients taking allopurinol, another gout drug. As people with gout problems already are at higher risk of heart disease, the FDA issued an "approvable" letter, noting that Uloric could be approved if this safety question were addressed.

Takeda resolved the safety question by performing a large new phase III clinical trial that enrolled more gout patients than the two previous phase III trials combined. The new study found no more deaths and no more heart problems in patients taking Uloric than in patients taking allopurinol.

Based on those results, an FDA advisory committee recommended Uloric's approval in November 2008. The FDA often follows the recommendations of its advisory committees, but it's not obligated to do so.

The most commonly reported adverse events in Uloric's clinical trials were liver function abnormalities, nausea, joint pain, and rash, according to Takeda Pharmaceuticals.

Today on WebMD

Mature woman exercise at home
Hint: Warming up first is crucial.
feet with gout
Quiz yourself.
woman in pain
One idea? Eat fish to curb inflammation.
senior couple walking
Can you keep your RA from progressing?
xray of knees with osteoarthritis
close up of man wearing dress shoes
feet with gout
close up of red shoe in shoebox
two male hands
Woman massaging her neck
5 Lupus Risk Factors